Topics

A Safety Study in Patients With Major Depressive Disorder

2014-08-27 03:12:29 | BioPortfolio

Summary

The primary objective of this study is to evaluate the long-term safety and tolerability of LY2216684 administered once daily (QD) in the adjunctive treatment with a selective serotonin reuptake inhibitor (SSRI) for up to approximately 1 year in patients with major depressive disorder (MDD) who are partial responders to their SSRI treatment.

Study Design

Control: Uncontrolled, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment

Conditions

Depressive Disorder, Major

Intervention

LY2216684

Location

For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559)
Indianapolis
Indiana
United States
46285

Status

Not yet recruiting

Source

Eli Lilly and Company

Results (where available)

View Results

Links

Published on BioPortfolio: 2014-08-27T03:12:29-0400

Clinical Trials [1890 Associated Clinical Trials listed on BioPortfolio]

A Study of Adjunctive Treatment to Antidepressant Therapy for Adults With Major Depressive Disorder

The primary purpose is to study the efficacy, safety, and tolerability of LY2216684 as an adjunctive treatment for patients with major depressive disorder (MDD), who were identified as par...

A Study for Patients With Major Depression

This is a study to assess the safety and effectiveness of LY2216684 compared to placebo in treating adults with major depressive disorder.

A Fixed Dose Study of Adjunctive Treatment to Antidepressant Therapy for Adults With Major Depressive Disorder

The primary purpose of this study is to assess whether at least one dose of LY2216684 (12 mg or 18 mg once daily) is superior to placebo once daily in the adjunctive treatment of patients ...

A Study in Adult Patients With Major Depressive Disorder

The purpose of this study is to assess whether LY2216684 is superior to placebo in the treatment of adult patients with major depressive disorder.

A Study of Pediatric Patients With Attention Deficit/Hyperactivity Disorder

The primary purpose of your child's participation in the study is to determine whether LY2216684 can help pediatric patients with ADHD, and assess the safety of LY2216684 and any side effe...

PubMed Articles [9946 Associated PubMed Articles listed on BioPortfolio]

Plasma Neuronal and Glial Markers and Anterior Cingulate Metabolite Levels in Major Depressive Disorder: A Pilot Study.

Neuroglial functions may be deteriorated in major depressive disorder (MDD).

Comparison of serum microbiome composition in bipolar and major depressive disorders.

Bipolar disorder and major depressive disorder are debilitating psychiatric conditions which can be difficult to differentiate; however, recent studies have suggested that microbiome composition may b...

Common and distinct neural activities in frontoparietal network in first-episode bipolar disorder and major depressive disorder: Preliminary findings from a follow-up resting state fMRI study.

It is difficult to distinguish bipolar disorder (BD) from major depressive disorder (MDD), especially with the initial depressive episode. In this study, we compared neural activities of BD and MDD pa...

Hyperactive frontolimbic and frontocentral resting-state gamma connectivity in major depressive disorder.

Major depressive disorder (MDD) is a system-level disorder affecting multiple functionally integrated cerebral networks. Nevertheless, their temporospatial organization and potential disturbance remai...

The early stage of face detection in patients with major depressive disorder: an ERP study.

To investigate whether perceptual processes involved in early stages of face processing are influenced by depressive disorder, the face detection and configural analysis were assessed by recording the...

Medical and Biotech [MESH] Definitions

A major affective disorder marked by severe mood swings (manic or major depressive episodes) and a tendency to remission and recurrence.

Marked depression appearing in the involution period and characterized by hallucinations, delusions, paranoia, and agitation.

A serotonin uptake inhibitor that is used as an antidepressive agent. It has been shown to be effective in patients with major depressive disorders and other subsets of depressive disorders. It is generally more useful in depressive disorders associated with insomnia and anxiety. This drug does not aggravate psychotic symptoms in patients with schizophrenia or schizoaffective disorders. (From AMA Drug Evaluations Annual, 1994, p309)

Inability to experience pleasure due to impairment or dysfunction of normal psychological and neurobiological mechanisms. It is a symptom of many PSYCHOTIC DISORDERS (e.g., DEPRESSIVE DISORDER, MAJOR; and SCHIZOPHRENIA).

An affective disorder manifested by either a dysphoric mood or loss of interest or pleasure in usual activities. The mood disturbance is prominent and relatively persistent.

More From BioPortfolio on "A Safety Study in Patients With Major Depressive Disorder"

Quick Search

Relevant Topic

The Top 100 Pharmaceutical Companies
Top 10 biotech and pharmaceutical companies worldwide based on market value in 2015 2015 ranking of the global top 10 biotech and pharmaceutical companies based on revenue (in billion U.S. dollars) Johnson & Johnson, U.S. 74...


Searches Linking to this Trial